Cerevance, a groundbreaking clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, is proud to announce that Craig Thompson, the company’s chief executive officer, will be participating in the upcoming SVB Global Biopharma Conference. Taking place virtually from January 31 to February 2, 2023, this event will provide a platform for Cerevance to showcase its cutting-edge developments and explore the latest advances in CNS disease treatments.
Cerevance is revolutionizing the pharmaceutical industry with its cutting-edge treatments for CNS disorders. Its lead therapeutic, CVN424, is a first-in-class, oral, non-dopaminergic compound that has been proven to have significant and clinically meaningful efficacy for Parkinson’s disease. The company harnesses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform to uncover novel target proteins that are specific to certain brain circuits or are over- or under-expressed in diseased brains. By partnering with over 25 brain banks and evaluating 12,000 human post-mortem brain tissue samples, Cerevance is on the cusp of delivering targeted treatments for Parkinson’s disease, Amyotrophic Lateral Sclerosis, and Alzheimer’s disease.